Navigation Links
GlaxoSmithKline Recognizes University of Michigan's Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award

New Award and Fellowship Supported by Multi-Year $1.3 Million Grant to the

ASCO Foundation

PHILADELPHIA, Aug. 16 /PRNewswire/ -- Daniel F. Hayes, MD, a University of Michigan oncologist and cancer researcher whose work in clinical and laboratory studies has advanced the management of breast cancer worldwide, was named today as the first winner of the annual Gianni Bonadonna Breast Cancer Award. Supported by a multi-year grant of more than $1.3 million from GlaxoSmithKline Oncology (GSK), the award will be presented by the American Society of Clinical Oncology (ASCO) and The ASCO Foundation at the Breast Cancer Symposium in San Francisco on September 7, 2007.

"GSK is honored to sponsor this award which is being presented to Dr. Daniel Hayes, a dedicated researcher who has been at the forefront of individualized breast cancer therapy," said Paolo Paoletti, MD, Senior Vice President of the Oncology Medicine Development Center at GlaxoSmithKline. "His contributions to the field of oncology have had an important impact on our knowledge about monitoring and managing the disease, and his findings have translated into real-world benefits for patients."

Dr. Hayes, who is Clinical Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center, is a widely recognized expert in breast cancer clinical research, particularly with new hormonal and chemotherapeutic treatments. He and his colleagues published the first reports on the CA15-3 blood test, currently used worldwide to evaluate breast cancer patients. Dr. Hayes' more recent research focuses on pharmacogenomics, and understanding the key role genes play in chemotherapy treatment.

The new award and an accompanying fellowship were created in honor of one of the giants of modern-day medical oncology, Dr. Gianni Bonadonna, of the Instituto Nazionale Tumori in Milan, Italy. Dr. Bonadonna was responsible for ground-breaking research in adjuvant treatment of breast cancer and the development of the combination chemotherapy regimen that remains the gold-standard treatment for Hodgkin's disease today.

"Gianni Bonadonna's work revolutionized the management and treatment of breast cancer," said Gabriel Hortobagyi, MD, immediate past president of ASCO. "Dr. Daniel Hayes is receiving a well-deserved recognition of his impressive research achievements and, I believe that Dr. Hayes, like Bonadonna, will continue to be an outstanding role model for younger oncology researchers."

About the Gianni Bonadonna Breast Cancer Award and Fellowship

'The Gianni Bonadonna Breast Cancer Award and Lecture', a $10,000 award, will be presented annually to a researcher of merit in the field of breast cancer. The award is accompanied by a fellowship grant, presented to an early-career breast cancer researcher who will work in the lab at the recipient's institution. 'The Gianni Bonadonna Breast Cancer Research Fellowship' will consist of a one-year grant of $50,000 in support of the fellow's research. The fellow will be announced at a later date.

In 1973, Dr. Bonadonna designed and conducted the first randomized study to test the activity of the CMF (cyclophosphamide, methotrexate and fluorouracil) combination chemotherapy as an adjuvant treatment in node-positive operable breast cancer. Adjuvant CMF proved to be effective in significantly reducing the risk of disease recurrence and death over a prolonged period of time (30 years).

About GlaxoSmithKline

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better, and live longer. For company information, visit GlaxoSmithKline at

GSK in Oncology

GSK Oncology is dedicated to producing innovations in cancer that will make profound differences in the lives of patients. Through GSK's "bench to bedside" approach, we are transforming the way treatments are discovered and developed, resulting in one of the most robust pipelines in the oncology sector. Our worldwide research in oncology includes partnerships with more than 160 cancer centers. GSK is developing a new generation of patient focused cancer treatments in prevention, supportive care, chemotherapy and targeted therapies.

SOURCE GlaxoSmithKline

Copyright©2007 PR Newswire.

Related biology technology :

1. GenTel acquires GlaxoSmithKline chip platform
2. Fermentation Cell Culture: University Style
3. Fueling our economy with the University of Wisconsin
4. CIO Leadership Series: Ed Meachen, University of Wisconsin System
5. University, business leaders convene in Wausau
6. University of South Florida expands GE Healthcare relationship
7. State and university form network for entrepreneurial outreach
8. University center offers speed boost to manufacturers
9. Building the modern public-purpose university should be UW Systems goal
10. University Research Park to add 20 incubator suites
11. University Research Park forms ties with German tech center
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015  Sorrento Therapeutics, ... developing new treatments for cancer and associated pain, announced ... Officer, will be presenting at the Aegis Capital ... Vegas :Event:Aegis Capital Corporation 2015 Growth ConferenceDate:Friday, ... room, The Encore @ The Wynn in Las ...
(Date:10/8/2015)... MANASSAS, Va. , Oct. 8, 2015  ATCC, ... announces today that it has been selected by The ... provide vital cell lines to academic, pharmaceutical, and biotechnology ... the United States , ... --> the United States , ...
(Date:10/8/2015)... 8, 2015 Celemics, a global pioneer of ... North American market with the establishment of Celemics America, ... Europe , has secured itself in ... methodology and sample preparation for DNA sequencing and genetic ... and somatic genetic testing more accurately, quickly, and cost ...
(Date:10/8/2015)... PORTLAND, Oregon , October 8, 2015 /PRNewswire/ ... . --> Global Biologics and Biosimilars ... added a report "Global Biologics and Biosimilars Industry ... Growth, Analysis and Forecast" is a professional and ... Biosimilars industry . ) , ...
Breaking Biology Technology:
... Merrimack Pharmaceuticals today announced that it will present at the Jefferies 2010 Global Life Sciences Conference ... provide a company overview at 11:00am EDT , Wednesday, June 9, 2010 at ... , , ... , , , ...
... June 1 Diplomat Specialty Pharmacy, the ... launch of Navigator Health Services, an independent division of ... pharmacy industry. The announcement was made by Diplomat Specialty ... who says that Navigator Health Services was formed in ...
... Calif. , June 1 Epeius Biotechnologies Corporation ( ... "Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Rexin-G as ... the ASCO Annual Meeting on June 8, 2010 . The ... Stanford University Medical Center, Palo Alto CA. ...
Cached Biology Technology:
(Date:9/10/2015)... , Sept. 10, 2015 Pursuant ... Clinic Wellness to create an interactive, image-based health ... health and wellness kiosk.  The unique assessment quantifies ... a number that suggests an individual,s biological age ... values as measured by the kiosk. ...
(Date:9/8/2015)... , Sept. 8, 2015   TREW Marketing ... the new survey, Smart Marketing for Engineers TM ... 580 engineering professionals reveals insightful findings about engineers, preferences ... types of content engineers most value and trust, and ... Marketers targeting technical audiences grapple with how to ...
(Date:9/2/2015)... YORK , Sept. 2, 2015 ... key concern for enterprises, banks, government organizations, telecommunications, ... and numeric keypads were previously being used to ... introduction of two-factor authentication, wherein individuals could gain ... two different components, such as hardware devices and ...
Breaking Biology News(10 mins):
... "We can make you and we can break you." If ... oxide would start something like that. But this song wouldn,t ... of Rice chemist James Tour demonstrates an environmentally friendly way ... version of single-atom-thick graphene expected to find use in all ...
... A novel approach detects genetically abnormal cells in the blood ... in tumor cells and increase in number with the severity ... The University of Texas MD Anderson Cancer Center report in ... patients in the study also had many times the number ...
... A University of Minnesota Medical School research team led ... a novel approach to ease the chronic and acute ... a mouse model of SCD, Gupta and University of ... that exhibited both musculoskeletal pain and temperature sensitivity, symptoms ...
Cached Biology News:
Request Info...
... digests duplex DNA in a 3'-> 5' ... nick, producing stretches of single-stranded DNA. Under ... III proceeds at a uniform rate yielding ... of exonucleolytic excision of deoxyribonucleotides by Exonuclease ...
Mouse monoclonal [HL-37] to HLA DQ1 + HLA DQ3 ( Abpromise for all tested applications)....
Biology Products: